glp 1 drugs adverse effects GI of Glucagon-Like Peptide-1 Receptor Agonists Gastrointestinal side effects of anti-obesity
Description
Additionally, mean monthly headache days were significantly reduced in the exenatide group compared to placebo, further supporting its therapeutic potential [99]
The Lancet Diabetes & Endocrinology, 6 (3), 237248
The growing awareness of the health risks associated with diabetes and obesity and the increasing emphasis on effective management strategies are fueling the demand for GLP-1 receptor agonists
After months of consistent weight loss on tirzepatide, the body adapts
